![logo](/logos/MRUS.webp)
Merus N.V.
NASDAQ:MRUS
50 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Merus N.V. |
Symbool | MRUS |
Munteenheid | USD |
Prijs | 50 |
Beurswaarde | 3,410,525,000 |
Dividendpercentage | 0% |
52-weken bereik | 19.805 - 61.61 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Sven Ante Lundberg M.D. |
Website | https://www.merus.nl |
An error occurred while fetching data.
Over Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)